Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article Free
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Lewis, S. J.
space
  arrow  Braunwald, E.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

ARTICLE

Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) Trial

right arrow Sandra J. Lewis, MD; Lemuel A. Moye, MD, PhD; Frank M. Sacks, MD; David E. Johnstone, MD; Gerald Timmis, MD; Jayne Mitchell, MS, ANP; Marian Limacher, MD; Sherron Kell, MD, MPH; Stephen P. Glasser, MD; Jane Grant, RN; Barry R. Davis, MD, PhD; Marc A. Pfeffer, MD, PhD; and Eugene Braunwald, MD

1 November 1998 | Volume 129 Issue 9 | Pages 681-689

Background: A majority of all myocardial infarctions occur in patients who are 65 years of age or older and have average cholesterol levels, but little information is available on whether cholesterol lowering in such patients reduces the rate of recurrent cardiovascular disease.

Objective: To determine whether pravastatin reduces the rate of recurrent cardiovascular events in older patients.

Design: Subset analysis of a randomized, controlled trial.

Setting: 80 hospitals and affiliates in the United States and Canada.

Patients: 1283 patients aged 65 to 75 years who had had myocardial infarction and had a plasma total cholesterol level less than 6.2 mmol/L (240 mg/dL) and a low-density lipoprotein cholesterol level of 3.0 to 4.5 mmol/L (115 to 174 mg/dL).

Intervention: Pravastatin, 40 mg/d, or placebo.

Measurements: Five-year event rates of major coronary events (coronary death, nonfatal myocardial infarction, angioplasty, or bypass surgery) and stroke.

Results: Major coronary events occurred in 28.1% of placebo recipients and 19.7% of pravastatin recipients (difference, 9.0 percentage points [95% CI, 4 to 13 percentage points]; relative risk reduction, 32%; P < 0.001). Coronary death occurred in 10.3% of the placebo group and in 5.8% of the pravastatin group (difference, 4.6 percentage points [CI, 1.9 to 6.5 percentage points]; relative risk reduction, 45%; P = 0.004). Stroke incidence was 7.3% in the placebo group and 4.5% in the pravastatin group (absolute reduction, 2.9 percentage points [CI, 0.3 to 4.5 percentage points]; relative reduction, 40%; P = 0.03). The numbers of older patients needed to treat for 5 years were 11 (CI, 8 to 24) to prevent a major coronary event and 22 (CI, 15 to 53) to prevent a coronary death. For every 1000 older patients treated, 225 cardiovascular hospitalizations would be prevented compared with 121 hospitalizations in 1000 younger patients.

Conclusions: In older patients with myocardial infarction and cholesterol levels in the average range, pravastatin is associated with a clinically important reduction in risk for major coronary events and stroke. Given the high cardiovascular event rate in older patients, the potential for absolute benefit in this age group is substantial.

Author and Article Information
space

For the CARE Investigators
For author affiliations and current author addresses, see end of text.
Grant Support: By an investigator-initiated grant from Bristol-Myers Squibb.
Requests for Reprints: Sandra J. Lewis, MD, Legacy Health System, Portland Cardiovascular Institute, 2222 NW Lovejoy Street, Portland, OR 97210.
Current Author Addresses: Dr. Lewis: Legacy Health System, Portland Cardiovascular Institute, 2222 NW Lovejoy Street, Portland, OR 97210.


Related articles in Annals:

Letters
Cholesterol Lowering in Older Patients
Kenneth S. Bannerman
Annals 1999 131: 155. [Full Text]  

Letters
Cholesterol Lowering in Older Patients
Sandra J. Lewis, Frank Sacks, AND Eugene Braunwald
Annals 1999 131: 155-156. [Full Text]  



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. J.M. de Craen, and M. J. Eisenberg
Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.
J. Am. Coll. Cardiol., January 1, 2008; 51(1): 37 - 45.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
C. G. P. Roberts, E. Guallar, and A. Rodriguez
Efficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis
J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 879 - 887.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
N. K. Wenger, S. J. Lewis, D. M. Herrington, V. Bittner, F. K. Welty, and for the Treating to New Targets Study Steering Com
Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease
Ann Intern Med, July 3, 2007; 147(1): 1 - 9.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Schneeweiss, A. R. Patrick, M. Maclure, C. R. Dormuth, and R. J. Glynn
Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction: A Population-Based Natural Experiment
Circulation, April 24, 2007; 115(16): 2128 - 2135.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. G. Ray, C. M. Norris, J. A. Udell, R. T. Tsuyuki, F. A. McAlister, M. L. Knudtson, and W. A. Ghali
Lipid-Lowering Therapy and Outcomes in Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 27 - 35.
[Abstract] [PDF]


Home page
CirculationHome page
K. K. Khush, D. D. Waters, V. Bittner, P. C. Deedwania, J. J.P. Kastelein, S. J. Lewis, and N. K. Wenger
Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study
Circulation, February 6, 2007; 115(5): 576 - 583.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Heart Protection Study Collaborative Group,*
N-Terminal Pro-B-Type Natriuretic Peptide, Vascular Disease Risk, and Cholesterol Reduction Among 20,536 Patients in the MRC/BHF Heart Protection Study
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 311 - 319.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
E. Selvin, J. Coresh, and F. L. Brancati
The burden and treatment of diabetes in elderly individuals in the u.s.
Diabetes Care, November 1, 2006; 29(11): 2415 - 2419.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. K. Ray, R. G. Bach, C. P. Cannon, R. Cairns, A. J. Kirtane, S. D. Wiviott, C. H. McCabe, E. Braunwald, C. M. Gibson, and for the PROVE IT-TIMI 22 Investigators
Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS
Eur. Heart J., October 1, 2006; 27(19): 2310 - 2316.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
E S Houslay, S J Cowell, R J Prescott, J Reid, J Burton, D B Northridge, N A Boon, D E Newby, and on behalf of the Scottish Aortic Stenosis and Lipi
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial
Heart, September 1, 2006; 92(9): 1207 - 1212.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Kronzon and P. A. Tunick
Aortic Atherosclerotic Disease and Stroke
Circulation, July 4, 2006; 114(1): 63 - 75.
[Full Text] [PDF]


Home page
HeartHome page
Prepared by: British Cardiac Society, British Hype
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Heart, December 1, 2005; 91(suppl_5): v1 - v52.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)
J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1116 - 1143.
[Full Text] [PDF]


Home page
CirculationHome page
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society
Circulation, September 20, 2005; 112(12): 1825 - 1852.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. M. Eddy, L. Schlessinger, and R. Kahn
Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
Ann Intern Med, August 16, 2005; 143(4): 251 - 264.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
W. S. Aronow
Should the NCEP III Guidelines Be Changed in Elderly and Younger Persons at High Risk for Cardiovascular Events?
J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2005; 60(5): 591 - 592.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. H. Smith, M. S. Petrie, J. D. Morrow, J. A. Oates, and D. E. Vaughan
The sterol response element binding protein regulates cyclooxygenase-2 gene expression in endothelial cells
J. Lipid Res., May 1, 2005; 46(5): 862 - 871.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
W. S. Aronow
Management of the Elderly Person After Myocardial Infarction
J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2004; 59(11): 1173 - 1185.
[Abstract] [Full Text] [PDF]


Home page
JRSMHome page
A. Thompson and N. J Temple
The case for statins: has it really been made?
J R Soc Med, October 1, 2004; 97(10): 461 - 464.
[Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
D. C Bjornson
Interpretation of Drug Risk and Benefit: Individual and Population Perspectives
Ann. Pharmacother., April 1, 2004; 38(4): 694 - 699.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. J Everly, P. C Heaton, and R. J Cluxton Jr
{beta}-Blocker Underuse in Secondary Prevention of Myocardial Infarction
Ann. Pharmacother., February 1, 2004; 38(2): 286 - 293.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
K. A Dornbrook-Lavender, M. T Roth, and J. A Pieper
Secondary Prevention of Coronary Heart Disease in the Elderly
Ann. Pharmacother., December 1, 2003; 37(12): 1867 - 1876.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
D. M. Eddy and L. Schlessinger
Validation of the Archimedes Diabetes Model
Diabetes Care, November 1, 2003; 26(11): 3102 - 3110.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
S. Ghosh and W. S. Aronow
Utilization of Lipid-Lowering Drugs in Elderly Persons With Increased Serum Low-Density Lipoprotein Cholesterol Associated With Coronary Artery Disease, Symptomatic Peripheral Arterial Disease, Prior Stroke, or Diabetes Mellitus Before and After an Educational Program on Dyslipidemia Treatment
J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M432 - 435.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. A. Allen Maycock, J. B. Muhlestein, B. D. Horne, J. F. Carlquist, T. L. Bair, R. R. Pearson, Q. Li, J. L. Anderson, and Intermountain Heart Collaborative Study
Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients
J. Am. Coll. Cardiol., November 20, 2002; 40(10): 1777 - 1785.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. O. Fedder, C. E. Koro, G. J. L'Italien, A. M. Gotto Jr, and L. H. Kuller
Primary Prevention Lipid-Lowering Drug Therapy * Response
Circulation, August 13, 2002; 106 (7): e35 - e36.
[Full Text] [PDF]


Home page
JAMAHome page
J. S. Benner, R. J. Glynn, H. Mogun, P. J. Neumann, M. C. Weinstein, and J. Avorn
Long-term Persistence in Use of Statin Therapy in Elderly Patients
JAMA, July 24, 2002; 288(4): 455 - 461.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
W. B. Applegate
Elderly Patients' Adherence to Statin Therapy
JAMA, July 24, 2002; 288(4): 495 - 497.
[Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
W. S. Aronow
Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events?
J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M411 - 413.
[Full Text]


Home page
Arch Intern MedHome page
J. Z. Ayanian, M. B. Landrum, and B. J. McNeil
Use of Cholesterol-Lowering Therapy by Elderly Adults After Myocardial Infarction
Arch Intern Med, May 13, 2002; 162(9): 1013 - 1019.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
W. S. Aronow, C. Ahn, and H. Gutstein
Incidence of New Atherothrombotic Brain Infarction in Older Persons With Prior Myocardial Infarction and Serum Low-Density Lipoprotein Cholesterol >=125 mg/dl Treated With Statins Versus No Lipid-Lowering Drug
J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2002; 57(5): M333 - 335.
[Abstract] [Full Text]


Home page
CirculationHome page
M. A. Williams, J. L. Fleg, P. A. Ades, B. R. Chaitman, N. H. Miller, S. M. Mohiuddin, I. S. Ockene, C. B. Taylor, and N. K. Wenger
Secondary Prevention of Coronary Heart Disease in the Elderly (With Emphasis on Patients >=75 Years of Age): An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention
Circulation, April 9, 2002; 105(14): 1735 - 1743.
[Full Text] [PDF]


Home page
Eur Heart JHome page
O. Faergeman
Estimation and reduction of cardiovascular risk in old people
Eur. Heart J., February 2, 2002; 23(4): 261 - 263.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. A. Kreisberg and A. Oberman
Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. H. Stein, C. M. Carlsson, K. Papcke-Benson, S. E. Aeschlimann, A. Bodemer, M. Carnes, and P. E. McBride
The effects of lipid-lowering and antioxidant vitamin therapies on flow-mediated vasodilation of the brachial artery in older adults with hypercholesterolemia
J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1806 - 1813.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
A. Gaw
Healthy ageing: addressing acute coronary syndrome?
Eur. Heart J. Suppl., November 1, 2001; 3(suppl_N): N11 - N15.
[Abstract] [PDF]


Home page
CirculationHome page
J. C. LaRosa
Prevention and Treatment of Coronary Heart Disease: Who Benefits?
Circulation, October 2, 2001; 104(14): 1688 - 1692.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
M. H. Davidson
Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 219 - 229.
[Abstract] [PDF]


Home page
QJMHome page
N. Kagansky, S. Levy, Y. Berner, E. Rimon, and H. Knobler
Cholesterol lowering in the older population: time for reassessment?
QJM, September 1, 2001; 94(9): 457 - 463.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. B. Braunstein, A. Cheng, G. Cohn, M. Aggarwal, C. M. Nass, and R. S. Blumenthal
Lipid Disorders : Justification of Methods and Goals of Treatment
Chest, September 1, 2001; 120(3): 979 - 988.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
J. Yarzebski, F. Spencer, R. J. Goldberg, D. Lessard, and J. M. Gore
Temporal Trends (1986-1997) in Cholesterol Level Assessment and Management Practices in Patients With Acute Myocardial Infarction: A Population-Based Perspective
Arch Intern Med, June 25, 2001; 161(12): 1521 - 1528.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
J. G. Ray, M. Mamdani, R. T. Tsuyuki, D. R. Anderson, E. L. Yeo, and A. Laupacis
Use of Statins and the Subsequent Development of Deep Vein Thrombosis
Arch Intern Med, June 11, 2001; 161(11): 1405 - 1410.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. Hunt, P. Young, J. Simes, W. Hague, S. Mann, D. Owensby, G. Lane, A. Tonkin, and for the LIPID Investigators
Benefits of Pravastatin on Cardiovascular Events and Mortality in Older Patients with Coronary Heart Disease Are Equal to or Exceed Those Seen in Younger Patients: Results from the LIPID Trial
Ann Intern Med, May 15, 2001; 134(10): 931 - 940.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. Malach, J. Quinley, P. J. Imperato, and M. Wallen
Improving Lipid Evaluation and Management in Medicare Patients Hospitalized for Acute Myocardial Infarction
Arch Intern Med, March 26, 2001; 161(6): 839 - 844.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
S. Bandyopadhyay, A.J. Bayer, and M.S. O'Mahony
Age and gender bias in statin trials
QJM, March 1, 2001; 94(3): 127 - 132.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
W. S. Aronow
Treatment of Older Persons With Hypercholesterolemia With and Without Cardiovascular Disease
J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2001; 56(3): 138M - 145.
[Abstract] [Full Text]


Home page
BMJHome page
S.
Recent advances: Geriatric
BMJ, January 13, 2001; 322(7278): 86 - 89.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. R. Chaitman and S. R. Bitar
Is ST segment elevation non-Q- wave myocardial infarction after thrombolytic therapy a new clinical entity that requires an invasive management strategy?
J. Am. Coll. Cardiol., January 1, 2001; 37(1): 26 - 29.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
M. H. Davidson, K. C. Maki, P. Marx, A. C. Maki, M. S. Cyrowski, N. Nanavati, and J.-C. Arce
Effects of Continuous Estrogen and Estrogen-Progestin Replacement Regimens on Cardiovascular Risk Markers in Postmenopausal Women
Arch Intern Med, November 27, 2000; 160(21): 3315 - 3325.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
M. Lye and C. Donnellan
GENERAL CARDIOLOGY: Heart disease in the elderly
Heart, November 1, 2000; 84(5): 560 - 566.
[Full Text]


Home page
Arch Intern MedHome page
A. Sgadari, R. A. Incalzi, G. Onder, C. Pedone, and G. Gambassi
Lipid-Lowering Therapy in Patients With Coronary Artery Disease: Sex or Age Bias?
Arch Intern Med, September 25, 2000; 160(17): 2684 - 2685.
[Full Text] [PDF]


Home page
QJMHome page
C.G. Isles and J.R. Paterson
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy
QJM, September 1, 2000; 93(9): 567 - 574.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. A. Ganz, K. M. Kuntz, G. A. Jacobson, and J. Avorn
Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction
Ann Intern Med, May 16, 2000; 132(10): 780 - 787.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. C. Hess, A. M. Demchuk, L. M. Brass, and F. M. Yatsu
HMG-CoA reductase inhibitors (statins): A promising approach to stroke prevention
Neurology, February 22, 2000; 54(4): 790 - 796.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. C. LaRosa, J. He, and S. Vupputuri
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
JAMA, December 22, 1999; 282(24): 2340 - 2346.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
B. J. Ansell, K. E. Watson, and A. M. Fogelman
An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines
JAMA, December 1, 1999; 282(21): 2051 - 2057.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
W. M. Landau
Is Cholesterol a Risk Factor for Stroke?: No
Arch Neurol, December 1, 1999; 56(12): 1521 - 1524.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
S. M. G